My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2025-126D
CBCC
>
Official Documents
>
2020's
>
2025
>
2025-126D
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
9/18/2025 10:43:54 AM
Creation date
9/8/2025 1:42:16 PM
Metadata
Fields
Template:
Official Documents
Official Document Type
Agreement
Approved Date
06/03/2025
Control Number
2025-126D
Agenda Item Number
13.D.1.
Entity Name
Rightway Healthcare, Inc.
Subject
Pharmacy Benefit Management Services Agreement
Document Relationships
2025-126
(Cover Page)
Path:
\Official Documents\2020's\2025
2025-126A
(Cover Page)
Path:
\Official Documents\2020's\2025
2025-126B
(Cover Page)
Path:
\Official Documents\2020's\2025
2025-126C
(Cover Page)
Path:
\Official Documents\2020's\2025
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
179
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
Docusign Envelope ID: 92lF7A24-D5CE-4BCC-9F3C-5E7844661266 <br />6270609010E520 <br />Amvuttra SOSY 25 MG/0.5ML <br />13.00% <br />662700150OF840 <br />Humira-Ped>/=40kg Crohns Start PSKT <br />80 MG/0.8ML <br />22.30% <br />662700150OF880 <br />Humira-Ped<40kg Crohns Starter PSKT <br />80 MG/0.8ML & 40MG/0.4ML <br />22.30% <br />6627001503F560 <br />Adalimumab-aaty (1 Pen) AJKT 80 <br />MG/0.8ML <br />13.00% <br />6627001504D540 <br />Hyrimoz-Crohns/UC Starter SOAJ 80 <br />MG/0.8ML <br />16.50% <br />6627001504D560 <br />Hyrimoz-Plaque Psoriasis Start SOAJ 80 <br />MG/0.8ML & 40MG/0.4ML <br />16.50% <br />6627001504E540 <br />Hyrimoz-Ped>/=40kg Crohn Start SOSY <br />80 MG/0.8ML <br />16.50% <br />6627001504E560 <br />Hyrimoz-Ped<40kg Crohn Starter SOSY <br />80 MG/0.8ML & 40MG/0.4ML <br />16.50% <br />858050952OE520 <br />Zilbrysq SOSY 16.6 MG/0.416ML <br />13.00% <br />858050952OE530 <br />Zilbrysq SOSY 23 MG/0.574ML <br />13.00% <br />858050952OE540 <br />Zilbrysq SOSY 32.4 MG/0.81ML <br />13.00% <br />8582004010E520 <br />Firazyr SOSY 30 MG/3ML <br />40.00% <br />40.00% <br />858420402OE510 <br />Takhzyro SOSY 150 MG/ML <br />13.00% <br />858420402OE520 <br />Takhzyro SOSY 300 MG/2ML <br />16.50% <br />902505180OD520 <br />Bimzelx SOAJ 160 MG/ML <br />19.44% <br />9025051800E520 <br />Bimzelx SOSY 160 MG/ML <br />17.00% <br />902505707OF820 <br />Skyrizi (150 MG Dose) PSKT 75 <br />MG/0.83ML <br />21.35% <br />9025057500E520 <br />Cosentyx SOSY 150 MG/ML <br />19.15% <br />902505777OE530 <br />Spevigo SOSY 150 MG/ML <br />13.00% <br />9079355510D420 <br />Nemluvio AUIJ 30 MG <br />14.00% <br />994050704OE520 <br />Enspryng SOSY 120 MG/MI, <br />15.50% <br />9948601000B720 <br />Vijoice TBPK 50 MG <br />16.00% <br />9948601000B730 <br />Vijoice TBPK 125 MG <br />13.00% <br />9948601000B740 <br />Vijoice TBPK 200 & 50 MG <br />13.00% <br />71 <br />This document is CONFIDENTIAL AND PROPRIETARY to RIGHTWAY Healthcare, Inc. and may not be reproduced, <br />transmitted, published, or disclosed to others without the prior written authorization of RIGHTWAY Healthcare, Inc. <br />
The URL can be used to link to this page
Your browser does not support the video tag.